English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  51185838    線上人數 :  610
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"ann lii cheng"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 436-445 / 690 (共69頁)
<< < 39 40 41 42 43 44 45 46 47 48 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2021-08-31T06:29:40Z Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Bruix J.; Qin S.; Merle P.; Granito A.; Huang Y.-H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.-P.; Ollivier-Hourmand I.; Kudo M.; ANN-LII CHENG; Llovet J.M.; Finn R.S.; LeBerre M.-A.; Baumhauer A.; Meinhardt G.; Han G.
臺大學術典藏 2021-08-31T06:29:40Z Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database study Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; ANN-LII CHENG; Lai M.-S.; Yeh K.-H.
臺大學術典藏 2021-08-31T06:29:39Z The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21) Kuo S.-H.; Tsai H.-J.; Lin C.-W.; Yeh K.-H.; Lee H.-W.; Wei M.-F.; Shun C.-T.; Wu M.-S.; Hsu P.-N.; Chen L.-T.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:39Z Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer Liang Y.-H.; Wei C.-H.; Hsu W.-H.; Shao Y.-Y.; Lin Y.-C.; Chou P.-C.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏 2021-08-31T06:29:39Z Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL Kuo S.-H.; Chen L.-T.; Lin C.-W.; Yeh K.-H.; Shun C.-T.; Tzeng Y.-S.; Liou J.-M.; Wu M.-S.; Hsu P.-N.; ANN-LII CHENG
臺大學術典藏 2021-08-31T06:29:38Z Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2011) 55(5) (1041�V1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047)) Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F.
臺大學術典藏 2021-08-31T06:29:38Z Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric Cancer Tsai K.-F.; Liou J.-M.; Chen M.-J.; Chen C.-C.; Kuo S.-H.; Lai I.-R.; Yeh K.-H.; Lin M.-T.; Wang H.-P.; ANN-LII CHENG; Lin J.-T.; Shun C.-T.; Wu M.-S.
臺大學術典藏 2021-08-31T06:29:38Z Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; Lin Z.-Z.; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG; Carrasquilo J.A.
臺大學術典藏 2021-08-31T06:29:37Z Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study ANN-LII CHENG; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; Yeh K.-H.; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R.
臺大學術典藏 2021-08-31T06:29:37Z Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study Lu L.-C.; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; ANN-LII CHENG

顯示項目 436-445 / 690 (共69頁)
<< < 39 40 41 42 43 44 45 46 47 48 > >>
每頁顯示[10|25|50]項目